{"classes":[{"categories":[{"measurements":[{"comment":"Due to low accrual the upper limit for the confidence interval was not able to be determined.","groupId":"OG000","lowerLimit":"0.4","upperLimit":"NA","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"OS will be estimated with the method of KM, where KM curves will be drawn to aid with visualization and estimates provided with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.\n\nLetermovir: Given PO","id":"OG000","title":"Treatment (Letermovir)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From trial enrollment to the occurrence of death due to any cause, assessed up to 2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}